Overview: This session will begin to lay the foundation necessary for any learner on the basics of sleep wake and circadian physiology, definition of sleepiness and ability to understand the pathophysiology, as well as recognize the signs, symptoms, and associated burden of central disorders of hypersomnolence, like narcolepsy and idiopathic hypersomnia. The webinar will continue to build on this foundation by providing lessons learned from currently available treatments and discussing the future of novel compounds, like orexin agonists, with unique mechanisms of action and how they may impact sleep medicine and beyond.
Monday, December 2, 2024
8:30am – 10:00am Central Time
Webinar held via zoom
Speakers
Anne Marie Morse, DO (facilitator)
Director of Child Neurology and Pediatric Sleep Medicine at Janet Weis Children’s Hospital – Geisinger Health System.
Atul Malhotra, MD
Chief of pulmonary, critical care, and sleep medicine at the University of California, San Diego School of Medicine.
Emmanuel Mignot, MD, PhD
Craig Reynolds Professor of Sleep Medicine and Professor, by courtesy, of Genetics and of Neurology at Stanford University and Director of the Stanford Center for Narcolepsy.
Phyllis C. Zee, MD, PhD
Professor of Neurobiology, Benjamin and Virginia T. Boshes Professor in Neurology at Northwestern Medicine, and chief of the Division of Sleep Medicine and Director of the Center for Circadian and Sleep Medicine.
Learning Objectives
- Identify the pentad and non pentad features of narcolepsy.
- Understand the role of orexin in sleep wake control.
- Characterize the role of orexin in non sleep processes.
Registration is free but required. Register in advance. After registering, you will receive a confirmation email containing information about joining the webinar.
The webinar will be recorded and available later.
This opportunity is made possible by the Sleep Research Society Foundation with support from multiple stakeholders: Alkermes, Avadel, axsome, Centessa Pharmaceuticals, Eisai, Jazz Pharmaceuticals, Takeda Pharmaceuticals, and Zevra Therapeutics.
